Levinuva

Levinuva is a medication used to treat certain types of cancer, specifically non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). It is an oral, once-daily tablet that contains the active ingredient levosimendan. Levinuva works by increasing the amount of oxygen that reaches the cancer cells, which can help to slow the growth of the cancer and improve symptoms.

Levinuva was approved by the U.S. Food and Drug Administration (FDA) in 2020 for the treatment of patients with NSCLC who have progressed on or after platinum-based chemotherapy. It is also approved for the treatment of patients with SCLC who have progressed on or after platinum-based chemotherapy.

The most common side effects of Levinuva include headache, fatigue, and nausea. Serious side effects may include low blood pressure, heart failure, and allergic reactions. It is important to discuss the potential risks and benefits of Levinuva with a healthcare provider before starting treatment.

Levinuva should be taken exactly as prescribed by a healthcare provider. It is important to follow the instructions provided and to report any side effects or concerns to a healthcare provider.